Cited by 42Advanced MRI Techniques and ApplicationsAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Longitudinal Assessment of Amyloid Pathology in Transgenic ArcAβ Mice Using Multi-Parametric Magnetic Resonance Imaging

Open access
Klohs, Jan, Politano, Igna Wojtyna, Deistung, Andreas, Grandjean, Joanes, Drewek, Anna, Dominietto, Marco, Keist, Ruth, Schweser, Ferdinand +4 more·2013·PLoS ONE

Abstract

Magnetic resonance imaging (MRI) can be used to monitor pathological changes in Alzheimer's disease (AD). The objective of this longitudinal study was to assess the effects of progressive amyloid-related pathology on multiple MRI parameters in transgenic arcAβ mice, a mouse model of cerebral amyloidosis. Diffusion-weighted imaging (DWI), T1-mapping and quantitative susceptibility mapping (QSM), a novel MRI based technique, were applied to monitor structural alterations and changes in tissue composition imposed by the pathology over time. Vascular function and integrity was studied by assessing blood-brain barrier integrity with dynamic contrast-enhanced MRI and cerebral microbleed (CMB) load with susceptibility weighted imaging and QSM. A linear mixed effects model was built for each MRI parameter to incorporate effects within and between groups (i.e. genotype) and to account for changes unrelated to the disease pathology. Linear mixed effects modelling revealed a strong association of all investigated MRI parameters with age. DWI and QSM in addition revealed differences between arcAβ and wt mice over time. CMBs became apparent in arcAβ mice with 9 month of age; and the CMB load reflected disease stage. This study demonstrates the benefits of linear mixed effects modelling of longitudinal imaging data. Moreover, the diagnostic utility of QSM and assessment of CMB load should be exploited further in studies of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0066097

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Transgenic mice expressing different human APP mutations exhibit pronounced vascular pathology including severe BBB permeability changes, microbleeds, BBB leakages of blood-derived molecules, impaired Aβ clearance at the BBB, endothelial cell degeneration, loss of VSMCs and pericytes, and CAA.

    “Similar to humans, transgenic mice expressing different human APP mutations exhibit pronounced vascular pathology including severe BBB permeability changes (322, 467, 579, 606), microbleeds (56, 321, 322, 336, 579), BBB leakages of blood-derived molecules (109, 331, 336, 467, 513), impaired A 𝛃 clearance at the BBB (57, 137, 464, 512), endothelial cell degeneration (336, 513), loss of VSMCs (336,”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [322]

    The Discussion (page unavailable) describes pronounced vascular pathology in arcAβ mice, including CAA-affected vessels, fibrinogen deposition, loss of vascular smooth muscle cells, BBB leakage, and microbleeds. It does not establish impaired Aβ clearance at the BBB, endothelial degeneration, or pericyte loss. Its own DCE-MRI assessment found no evident BBB leakage, so it does not support the claim of severe permeability changes. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Klohs, J., Politano, I. W., Deistung, A., Grandjean, J., Drewek, A., Dominietto, M., Keist, R., Schweser, F., Reichenbach, J. R., Nitsch, R. M., Knuesel, I., & Rudin, M.
Affiliations
  • University of Zurich (CH)
  • Jena University Hospital (DE)
  • ETH Zurich (CH)
Corresponding author
Klohs, Jan
Venue
PLoS ONE
Published
2013-06-19
Volume
8
Issue
6
Pages
e66097
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2041824340
Cited by
42
References
57
Citations by year
2026: 3 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 8 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 1
FWCI
2.33
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection (cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • National Science Foundation (310030)
  • Carl-Zeiss-Stiftung
  • Deutsche Forschungsgemeinschaft (RE1123/9-2)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (132629, 112835, 310030, 3100A0, 126029)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, cerebral amyloidosis, amyloid pathology, quantitative susceptibility mapping, cerebral microbleeds, blood-brain barrier integrity, diffusion-weighted imaging, T1 mapping, longitudinal MRI, disease staging
MeSH terms
Animals, Blood-Brain Barrier, Brain, Disease Models, Animal, Longitudinal Studies, Male, Mice, Transgenic, Linear Models, Cerebral Amyloid Angiopathy, Diffusion Magnetic Resonance Imaging, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review